ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
엔사티닙 시장 규모는 최근 급속도로 확대되고 있습니다. 2024년 9억 7,000만 달러에서 2025년에는 10억 9,000만 달러에 달하고, CAGR 11.4%로 확대될 전망입니다. 과거 조사기간에 관찰된 성장은 유리한 환급 결정, 폐암 표적 치료에 대한 지불자의 적용 범위 확대, 조기 진단 이니셔티브의 성장, 표적 치료의 이점에 대한 환자와 임상의의 의식 증가, 맞춤 의료의 중시 증가와 관련이 있습니다.
엔사티닙 시장 규모는 향후 수년간 급성장할 것으로 예측됩니다. 2029년에는 연평균 복합 성장률(CAGR) 11.0%로 16억 5,000만 달러로 성장할 전망입니다. 예측기간에 예측되는 성장은 바이오마커 스크리닝의 지속적인 확대, 비소세포 폐암의 유병률의 상승, 표적암 치료에 대한 수요 증가, 결과 기반 치료 모델의 채용 확대, 환자의 편리성 중시 증가에 기인하고 있습니다. 예측기간 중 주요 동향으로는 진단기술의 진보, AI를 활용한 시험 매칭, 연구기관 및 의료 제공자와의 전략적 제휴, 병용요법의 개발, 연구개발 투자 증가 등을 들 수 있습니다.
폐암 환자 수 증가가 엔사티닙 시장의 성장을 가속화할 것으로 예측되고 있습니다. 폐암은 폐의 비정상적인 세포가 통제 불능한 수준으로 증식하고, 종종 종양을 형성하여 호흡을 방해하고, 다른 신체 부위로 전이할 수 있는 질환입니다. 대기 오염 중에서 특히 미세 입자상 물질에 대한 장기적인 노출은 폐 조직을 서서히 손상시킴으로써 폐암의 발생률을 증가시키는 원인이 되고 있습니다. 엔사티닙은 ALK 양성 비소세포 폐암 환자의 종양 증식을 제어하는 ALK 유전자의 비정상적인 활성을 억제함으로써 폐암을 치료합니다. 예를 들어 미국 질병예방관리센터(CDC)의 데이터에 따르면 미국의 신규 폐암 환자는 2022년 21만 8,893명에서 2023년 23만 8,340명으로 증가했습니다. 이 폐암의 유병률 증가가 엔사티닙 시장의 확대를 뒷받침하고 있습니다.
건강 관리에 대한 지출 증가는 엔사티닙 시장의 성장을 더욱 촉진할 것으로 예측됩니다. 건강 관리 지출은 개인, 조직, 정부가 의료 서비스, 공중 보건 이니셔티브, 약물 및 관련 활동에 지출하는 총 금액을 의미합니다. 인구가 노화되고 보다 전문적인 케어가 필요함에 따라, 헬스케어 지출은 증가세에 있으며 전반적인 비용 증가로 이어집니다. 이러한 지출은 엔사티닙과 같은 고급 암 치료제를 이용할 수 있게 되어 의료시설에서의 이용 가능성을 지원하고 있습니다. 예를 들어, 미국 의사회 보고서에 따르면 미국 의료비는 2023년 7.5% 증가했고, 4조 9,000억 달러, 1인당 1만 4,570달러에 이르렀으며, 2022년 4.6% 증가에 비해 크게 증가했습니다. 이 건강 관리 지출 증가는 엔사티닙 시장의 확대에 중요한 역할을 합니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향과 전략
제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁과 관세, 그리고 코로나 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석과 전략 분석 프레임워크
세계의 엔사티닙 : PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
최종 이용 산업의 분석
세계의 엔사티닙 시장 : 성장률 분석
세계의 엔사티닙 시장 실적 : 규모와 성장(2019-2024년)
세계의 엔사티닙 시장 예측 : 규모와 성장(2024-2029년, 2034년)
세계의 엔사티닙 : 총 시장 규모(TAM)
제6장 시장 세분화
세계의 엔사티닙 시장 : 약제 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
경구제
주사제
세계의 엔사티닙 시장 : 환자 속성별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
소아환자
성인환자
노인환자
세계의 엔사티닙 시장 : 적응증별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
비소세포 폐암(NSCLC)
기타 폐암
새로운 적응증의 가능성
세계의 엔사티닙 시장 : 치료 라인별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
퍼스트라인 치료
세컨드라인 라인 치료
써드라인 이후의 치료
세계의 엔사티닙 시장 : 최종사용자별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
병원
전문 클리닉
기타 최종 사용자
세계의 엔사티닙 시장 세분화 : 경구제 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
캡슐제
태블릿
액체 제형
경구 현탁용 분말 제제
세계의 엔사티닙 시장 세분화 : 주사제 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
바이알
프리필드 주사기
동결건조 분말
주사제
제7장 지역별/국가별 분석
세계의 엔사티닙 시장 : 지역별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
세계의 엔사티닙 시장 : 국가별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도와 기업 프로파일
엔사티닙 시장 : 경쟁 구도
엔사티닙 시장 : 기업 프로파일
Xcovery Holdings Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
Betta Pharmaceuticals Co. Ltd. : 개요, 제품 및 서비스, 전략 및 재무 분석
제31장 세계 시장 경쟁 벤치마킹과 대시보드
제32장 주요 인수합병(M&A)
제33장 최근 시장 동향
제34장 시장의 잠재력이 높은 국가, 부문, 전략
엔사티닙 시장(2029년) : 새로운 기회를 제공하는 국가
엔사티닙 시장(2029년) : 새로운 기회를 제공하는 부문
엔사티닙 시장(2029년) : 성장 전략
시장 동향에 기초한 전략
경쟁 전략
제35장 부록
CSM
영문 목차
영문목차
Ensartinib is a targeted cancer therapy available in oral or injectable forms that acts as a tyrosine kinase inhibitor. It specifically blocks the activity of the anaplastic lymphoma kinase (ALK) protein, which contributes to the uncontrolled growth and spread of certain cancer cells. Ensartinib is primarily prescribed for patients with ALK-positive non-small cell lung cancer, particularly those who have developed resistance or intolerance to earlier-generation ALK inhibitors, helping to slow tumor progression and improve clinical outcomes.
The main drug types of ensartinib include oral and injectable formulations. Oral ensartinib is administered by mouth, typically as tablets or capsules. It is used across different patient demographics, including pediatric, adult, and geriatric populations, for indications such as non-small cell lung cancer (NSCLC), other lung cancers, and potential new therapeutic applications. Treatment lines include first-line, second-line, and third-line or later therapy. Key end users include hospitals, specialty clinics, and other healthcare providers.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the pharmaceutical companies contend with tariffs on APIs, glass vials, and lab equipment inputs with few alternative sources. Generic drug makers, operating on razor-thin margins, are especially vulnerable, with some reducing production of low-profit medicines. Biotech firms face delays in clinical trials due to tariff-related shortages of specialized reagents. In response, the industry is expanding API production in India and Europe, increasing inventory stockpiles, and pushing for trade exemptions for essential medicines.
The ensartinib market research report is one of a series of new reports from The Business Research Company that provides ensartinib market statistics, including the ensartinib industry's global market size, regional shares, competitors with an ensartinib market share, detailed ensartinib market segments, market trends and opportunities, and any further data you may need to thrive in the ensartinib industry. This Ensartinib market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The ensartinib market size has grown rapidly in recent years. It will grow from $0.97 billion in 2024 to $1.09 billion in 2025 at a compound annual growth rate (CAGR) of 11.4%. The growth observed during the historic period can be linked to favorable reimbursement decisions, expanded payer coverage for targeted lung cancer therapies, growth in early diagnosis initiatives, rising awareness among patients and clinicians of the benefits of targeted therapies, and increased emphasis on personalized medicine.
The ensartinib market size is expected to see rapid growth in the next few years. It will grow to $1.65 billion in 2029 at a compound annual growth rate (CAGR) of 11.0%. The growth projected for the forecast period can be attributed to continued expansion of biomarker screening, rising prevalence of non-small cell lung cancer, increasing demand for targeted cancer therapies, growing adoption of outcome-based treatment models, and heightened focus on patient convenience. Key trends during the forecast period include advancements in diagnostic techniques, AI-enabled trial matching, strategic collaborations with research institutions and healthcare providers, development of combination therapies, and increased investment in research and development.
The rising number of lung cancer cases is expected to drive the growth of the ensartinib market. Lung cancer is a condition where abnormal cells in the lungs multiply uncontrollably, often forming tumors that disrupt breathing and may spread to other body parts. Prolonged exposure to air pollution, especially fine particulate matter, contributes to the increasing incidence of lung cancer by gradually damaging lung tissue. Ensartinib treats lung cancer by inhibiting the abnormal activity of the ALK gene, which regulates tumor growth in patients with ALK-positive non-small cell lung cancer. For example, data from the Centers for Disease Control and Prevention (CDC) shows that new lung cancer cases in the United States rose from 218,893 in 2022 to 238,340 in 2023. This growing prevalence of lung cancer is driving the expansion of the ensartinib market.
The rise in healthcare spending is expected to further fuel the growth of the ensartinib market. Healthcare expenditure refers to the total amount spent by individuals, organizations, or governments on medical services, public health initiatives, medications, and related activities. As the population ages and requires more specialized care, healthcare spending continues to rise, leading to increased overall costs. This spending supports the availability of advanced cancer treatments such as ensartinib, helping ensure they are accessible in medical facilities. For instance, the American Medical Association reported that health spending in the U.S. grew by 7.5% in 2023, reaching $4.9 trillion, or $14,570 per person, a significant increase compared to the 4.6% growth in 2022. This rising healthcare expenditure plays a key role in expanding the ensartinib market.
Leading companies in the ensartinib market are concentrating on gaining regulatory approvals to improve patient access in major global markets and secure expanded indications for treating additional ALK-positive NSCLC cases. Regulatory approvals are granted by health authorities once a drug demonstrates its safety, efficacy, and quality. For example, in December 2024, Xcovery Holdings, Inc. received FDA approval for ensartinib (branded as Ensacove) to treat adult patients with ALK-positive locally advanced or metastatic non-small cell lung cancer (NSCLC) who have not been previously treated with an ALK inhibitor. This approval was based on the phase 3 eXALT3 trial, which showed that ensartinib significantly improved progression-free survival compared to crizotinib (25.8 months vs 12.7 months), although overall survival rates were similar between the two groups. Ensartinib, a second-generation ALK inhibitor, targets abnormal ALK proteins and can overcome resistance, though it has side effects such as rash, muscle pain, constipation, cough, itching, nausea, swelling, fever, and fatigue.
Major players in the ensartinib market are Xcovery Holdings Inc., Betta Pharmaceuticals Co. Ltd.
North America was the largest region in the ensartinib market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in ensartinib report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the ensartinib market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The ensartinib market consists of sales of ensartinib capsules, tablets, liquid formulations, prefilled syringes, and lyophilized powder. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Ensartinib Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on ensartinib market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for ensartinib ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The ensartinib market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:1) By Drug Type: Oral; Injectable
2) By Patient Demographics: Pediatric Patients; Adult Patients; Geriatric Patients
3) By Indication: Non-Small Cell Lung Cancer (NSCLC); Other Lung Cancers; Potential New Indications
4) By Treatment Line: First-Line Treatment; Second-Line Treatment; Third-Line And Beyond Treatment
5) By End-User: Hospitals; Specialty Clinics; Other End-Users
Subsegments:
1) By Oral: Capsules; Tablets; Liquid Formulations; Powder For Oral Suspension
2) By Injectable: Vials; Prefilled Syringes; Lyophilized Powder; Solution For Injection
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Ensartinib Market Characteristics
3. Ensartinib Market Trends And Strategies
4. Ensartinib Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
4.1. Supply Chain Impact from Tariff War & Trade Protectionism
5. Global Ensartinib Growth Analysis And Strategic Analysis Framework
5.1. Global Ensartinib PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Ensartinib Market Growth Rate Analysis
5.4. Global Ensartinib Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Ensartinib Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Ensartinib Total Addressable Market (TAM)
6. Ensartinib Market Segmentation
6.1. Global Ensartinib Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Oral
Injectable
6.2. Global Ensartinib Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Pediatric Patients
Adult Patients
Geriatric Patients
6.3. Global Ensartinib Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Non-Small Cell Lung Cancer (NSCLC)
Other Lung Cancers
Potential New Indications
6.4. Global Ensartinib Market, Segmentation By Treatment Line, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
First-Line Treatment
Second-Line Treatment
Third-Line And Beyond Treatment
6.5. Global Ensartinib Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospitals
Specialty Clinics
Other End-Users
6.6. Global Ensartinib Market, Sub-Segmentation Of Oral, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Capsules
Tablets
Liquid Formulations
Powder For Oral Suspension
6.7. Global Ensartinib Market, Sub-Segmentation Of Injectable, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Vials
Prefilled Syringes
Lyophilized Powder
Solution For Injection
7. Ensartinib Market Regional And Country Analysis
7.1. Global Ensartinib Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Ensartinib Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8. Asia-Pacific Ensartinib Market
8.1. Asia-Pacific Ensartinib Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Ensartinib Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Ensartinib Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Ensartinib Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China Ensartinib Market
9.1. China Ensartinib Market Overview
9.2. China Ensartinib Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Ensartinib Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Ensartinib Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India Ensartinib Market
10.1. India Ensartinib Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Ensartinib Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Ensartinib Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan Ensartinib Market
11.1. Japan Ensartinib Market Overview
11.2. Japan Ensartinib Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Ensartinib Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Ensartinib Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia Ensartinib Market
12.1. Australia Ensartinib Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Ensartinib Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Ensartinib Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia Ensartinib Market
13.1. Indonesia Ensartinib Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Ensartinib Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Ensartinib Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea Ensartinib Market
14.1. South Korea Ensartinib Market Overview
14.2. South Korea Ensartinib Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Ensartinib Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Ensartinib Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe Ensartinib Market
15.1. Western Europe Ensartinib Market Overview
15.2. Western Europe Ensartinib Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Ensartinib Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Ensartinib Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK Ensartinib Market
16.1. UK Ensartinib Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Ensartinib Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Ensartinib Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17. Germany Ensartinib Market
17.1. Germany Ensartinib Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Ensartinib Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Ensartinib Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. France Ensartinib Market
18.1. France Ensartinib Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Ensartinib Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Ensartinib Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19. Italy Ensartinib Market
19.1. Italy Ensartinib Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Ensartinib Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Ensartinib Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20. Spain Ensartinib Market
20.1. Spain Ensartinib Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Ensartinib Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Ensartinib Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe Ensartinib Market
21.1. Eastern Europe Ensartinib Market Overview
21.2. Eastern Europe Ensartinib Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Ensartinib Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Ensartinib Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia Ensartinib Market
22.1. Russia Ensartinib Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Ensartinib Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Ensartinib Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America Ensartinib Market
23.1. North America Ensartinib Market Overview
23.2. North America Ensartinib Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Ensartinib Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Ensartinib Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA Ensartinib Market
24.1. USA Ensartinib Market Overview
24.2. USA Ensartinib Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Ensartinib Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Ensartinib Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25. Canada Ensartinib Market
25.1. Canada Ensartinib Market Overview
25.2. Canada Ensartinib Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Ensartinib Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Ensartinib Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America Ensartinib Market
26.1. South America Ensartinib Market Overview
26.2. South America Ensartinib Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Ensartinib Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Ensartinib Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil Ensartinib Market
27.1. Brazil Ensartinib Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Ensartinib Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Ensartinib Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East Ensartinib Market
28.1. Middle East Ensartinib Market Overview
28.2. Middle East Ensartinib Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Ensartinib Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Ensartinib Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29. Africa Ensartinib Market
29.1. Africa Ensartinib Market Overview
29.2. Africa Ensartinib Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Ensartinib Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Ensartinib Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
30. Ensartinib Market Competitive Landscape And Company Profiles
30.1. Ensartinib Market Competitive Landscape
30.2. Ensartinib Market Company Profiles
30.2.1. Xcovery Holdings Inc. Overview, Products and Services, Strategy and Financial Analysis
30.2.2. Betta Pharmaceuticals Co. Ltd. Overview, Products and Services, Strategy and Financial Analysis
31. Global Ensartinib Market Competitive Benchmarking And Dashboard
32. Key Mergers And Acquisitions In The Ensartinib Market
33. Recent Developments In The Ensartinib Market
34. Ensartinib Market High Potential Countries, Segments and Strategies
34.1 Ensartinib Market In 2029 - Countries Offering Most New Opportunities
34.2 Ensartinib Market In 2029 - Segments Offering Most New Opportunities
34.3 Ensartinib Market In 2029 - Growth Strategies
34.3.1 Market Trend Based Strategies
34.3.2 Competitor Strategies
35. Appendix
35.1. Abbreviations
35.2. Currencies
35.3. Historic And Forecast Inflation Rates
35.4. Research Inquiries
35.5. The Business Research Company
35.6. Copyright And Disclaimer
(주)글로벌인포메이션02-2025-2992kr-info@giikorea.co.kr ⓒ Copyright Global Information, Inc. All rights reserved.
